Evidence map›Paper›PMID 32826305›Full record

ArticleGut2021

Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.

Soledad A Camolotto, Veronika K Belova, Luke Torre-Healy, Jeffery M Vahrenkamp, Kristofer C Berrett, Hannah Conway, Jill Shea, Chris Stubben, Richard Moffitt, Jason Gertz and 1 more

Open access · greenAbstract read
In one paragraph

Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. The role of HNF4α in adenocarcinoma.Biochemical Society transactions · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Knockdown of SIX4 inhibits pancreatic cancer cells via apoptosis induction.Medical oncology (Northwood, London, England) · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Soledad A CamolottoDepartment of Pathology, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Veronika K BelovaDepartment of Pathology, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Luke Torre-HealyDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.
Jeffery M VahrenkampDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Kristofer C BerrettDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Hannah ConwayHCI Clinical Trials Operations, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Jill SheaDepartment of Surgery, University of Utah, Salt Lake City, Utah, USA.
Chris StubbenBioinformatics Shared Resource, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Richard MoffittDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.
Jason GertzDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA.
Eric L SnyderDepartment of Pathology, Huntsman Cancer Institute, University of Utah Health, Salt Lake City, Utah, USA eric.snyder@hci.utah.edu.ORCID 0000-0003-3591-3195
University of Utah · USStony Brook University · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008444 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI FROHMAN, MICHAEL A. · 1992 to 2024
$12.6M
Transcriptional Regulation of Lung Cancer IdentityR01CA212415 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Eric Lee Snyder · 2017 to 2026
$3.2M
Patho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the LungR01CA240317 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI MAEDA, YUTAKA, SNYDER, ERIC LEE · 2020 to 2024
$3.1M
Lineage Specifiers Governing Pancreatic Cancer Growth and Molecular SubtypeR01CA237404 · NCI · UNIVERSITY OF UTAH · PI SNYDER, ERIC LEE · 2020 to 2024
$1.9M
Univ of Utah Cell Sorter for Flow Cytometry CoreS10RR026802 · NCRR · UNIVERSITY OF UTAH · PI GREEN, WAYNE FRANCIS · 2010 to 2010
$500k
Regulation of pancreatic ductal adenocarcinoma progression by Hnf4aR21CA194764 · NCI · UNIVERSITY OF UTAH · PI SNYDER, ERIC LEE · 2015 to 2016
$360k
NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA212415NCI NIH HHS R01 CA237404NCI NIH HHS R01 CA240317NCI NIH HHS R21 CA194764NCRR NIH HHS S10 RR026802NIGMS NIH HHS T32 GM008444
6 · The paper itself

Abstract

objectivePancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival of less than 5%. Transcriptomic analysis has identified two clinically relevant molecular subtypes of PDAC: classical and basal-like. The classical subtype is characterised by a more favourable prognosis and better response to chemotherapy than the basal-like subtype. The classical subtype also expresses higher levels of lineage specifiers that regulate endodermal differentiation, including the nuclear receptor hepatocyte nuclear factor 4 α (HNF4α). The objective of this study is to evaluate the role of HNF4α, SIX4 and SIX1 in regulating the growth and molecular subtype of PDAC.

designWe manipulate the expression of HNF4α, SIX4 and SIX1 in multiple in vitro and in vivo PDAC models. We determine the consequences of manipulating these genes on PDAC growth, differentiation and molecular subtype using functional assays, gene expression analysis and cross-species comparisons with human datasets.

resultsWe show that HNF4α restrains tumour growth and drives tumour cells toward an epithelial identity. Gene expression analysis of murine models and human tumours shows that HNF4α activates expression of genes associated with the classical subtype. HNF4α also directly represses SIX4 and SIX1, two mesodermal/neuronal lineage specifiers expressed in the basal-like subtype. Finally, SIX4 and SIX1 drive proliferation and regulate differentiation in HNF4α-negative PDAC.

conclusionOur data show that HNF4α regulates the growth and molecular subtype of PDAC by multiple mechanisms, including activation of the classical gene expression programme and repression of SIX4 and SIX1, which may represent novel dependencies of the basal-like subtype.

Indexed as

AnimalsCarcinoma, Pancreatic DuctalDisease Models, AnimalGene Expression ProfilingGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 4Homeodomain ProteinsHumansMicePancreatic NeoplasmsTrans-ActivatorsHepatocyte Nuclear Factor 4HNF4A protein, humanHnf4a protein, mouseHomeodomain ProteinsSIX1 protein, humanSix1 protein, mouseSIX4 protein, humanSix4 protein, mouseTrans-Activatorsgene expressionmolecular mechanismspancreatic cancer

Identifiers

PMID32826305
PMCPMC7945295
OpenAlexW3080408404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.